Fortunately, the diagnosis and treatment of this cancer type is experiencing a paradigm shift away from invasive, gland removing treatments to a more precise approach that is minimally invasive and increasingly more localized. This shift promises to show equal therapeutic outcomes while significantly improving after-treatment quality of life. This positive trend is to a large extent driven by utilization of integrated imaging methods and informatics to better diagnose, define and target cancer hotspots within the prostate.
Every patient’s cancer is unique and displays individual variations, triggering radiation oncology to invariably pursue a more personalized medicine approach. Cancer is a genomic disease and this individualistic approach provides the opportunity for better understanding of specific mutations, compared to a cancer type – in turn allowing for a more customized and targeted treatment plan.
Diagnostic innovations, especially for radiation oncology, are key to driving precision medicine forward and will be integral in providing radiation oncologists with additional tools for effective treatment planning and delivery. Philips is advancing this trend by combining all major imaging modalities for oncology care with treatment planning software, advanced visualization and image processing, and the emerging areas of digital pathology and genomics. The innovative work that’s emerging is having a meaningful impact on patients and the clinicians who treat them, with the promise of even more impact tomorrow.
, 2 American Cancer Society: Cancer Facts & Figures 2016, Atlanta. American Cancer Society 2016